Brind.
  1. Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.
  2. Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.
  3. Natera, Genentech, and NRG Oncology are involved in cancer diagnostics/treatment, specifically Natera's Signatera test in the ARCHER trial.

Natera plans commercial launch in Japan by end of 2026 after the PMDA approved its Signatera test for colorectal cancer.

3 reports, 2 independent Updated Sep 22
Gone quiet
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Natera plans commercial launch in Japan by end of 2026 after the PMDA approved its Signatera test for colorectal cancer.

Who's involved

What this event is mainly about
NateraPharmaceuticals and Medical Devices Agency

Keep exploring

Part of

Natera, Genentech, and NRG Oncology are involved in cancer diagnostics/treatment, specifically Natera's Signatera test in the ARCHER trial. All 1 developments

Within Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.

The entities involved

Coverage

Newest first; wire copies grouped